| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 8,180 | $30 | $277.9K |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 44,400 | $1 | $177.6K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 6,640 | $30 | $172.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,180 | $100 | $114.8K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 10,350 | $10 | $113.8K |
| J0897 | Injection, denosumab, 1 mg | 6,120 | $20 | $110.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 210 | $120 | $24K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 340 | $70 | $22.6K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 230 | $60 | $14.5K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 100 | $130 | $13.2K |